MIT physicists have captured the first images of "second sound," a wave-like heat phenomenon in a superfluid, offering insights into thermal conductivity.

MIT scientists, with the Singapore-MIT Alliance for Research and Technology, have created a microfluidic device to improve the safety of cell therapy treatments by removing tumorigenic cells.

Boston University's CTE Center study shows a link between CTE pathology and cognitive/behavioral symptoms, moving closer to diagnosing CTE in the living.

Researchers at MIT and the University of Texas have found new ways to control magnetic waves with terahertz light, potentially advancing quantum computing.

MIT experts applied Weyl's law to improve machine learning efficiency, cutting down on the training data needed for AI systems, as presented at a December 2023 conference.

A study at Massachusetts General Hospital uses Neuropixels probes to advance understanding of the brain's speech production, with implications for treating language disorders.

A study by MIT researchers revealed that doctors have more difficulty diagnosing diseases on darker skin, underscoring the need for better training and potential AI assistance.

An AI system from BIDMC and MIT may allow earlier detection of pancreatic cancer, increasing survival rates by identifying at-risk individuals 18 months prior to usual diagnosis.

Research from UMass Amherst shows that during COVID-19, hospitality firms that cut CEO pay rather than jobs gained loyalty from ethically minded customers, according to a study published in Cornell Hospitality Quarterly.

MIT astronomers have doubled the number of known tidal disruption events (TDEs) by observing 18 black holes eating stars using infrared data from NEOWISE.

A study reveals that climate change may have the most severe impact on the oldest African elephants, crucial for ecosystem balance and elephant populations.

MIT and Brigham and Women's Hospital researchers have developed a novel microscopy technique that provides unprecedented detail of brain tissue, potentially altering brain tumor diagnosis and treatment.

Biogen ends its controversial Alzheimer's drug Aduhelm due to efficacy doubts and commercial challenges, facing a $60 million cost and shifting focus to a newer treatment, Leqembi.